JP2019534867A - カンナビノイド受容体結合リガンドを含む組成物 - Google Patents

カンナビノイド受容体結合リガンドを含む組成物 Download PDF

Info

Publication number
JP2019534867A
JP2019534867A JP2019516407A JP2019516407A JP2019534867A JP 2019534867 A JP2019534867 A JP 2019534867A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A JP2019534867 A JP 2019534867A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
thc
composition according
receptor binding
cannabinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019516407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534867A5 (enExample
Inventor
ベルンハルト グンター，
ベルンハルト グンター，
フランク ルッシャー，
フランク ルッシャー，
ソンニャ クレッサー，
ソンニャ クレッサー，
フィリップ スティーヴェン
フィリップ スティーヴェン
Original Assignee
ノバリック ゲーエムベーハー
ノバリック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバリック ゲーエムベーハー, ノバリック ゲーエムベーハー filed Critical ノバリック ゲーエムベーハー
Publication of JP2019534867A publication Critical patent/JP2019534867A/ja
Publication of JP2019534867A5 publication Critical patent/JP2019534867A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019516407A 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物 Pending JP2019534867A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16191194.6 2016-09-28
EP16191194 2016-09-28
EP17168172 2017-04-26
EP17168172.9 2017-04-26
PCT/EP2017/074545 WO2018060282A1 (en) 2016-09-28 2017-09-27 Compositions comprising a cannabinoid receptor binding ligand

Publications (2)

Publication Number Publication Date
JP2019534867A true JP2019534867A (ja) 2019-12-05
JP2019534867A5 JP2019534867A5 (enExample) 2020-04-09

Family

ID=59966776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516407A Pending JP2019534867A (ja) 2016-09-28 2017-09-27 カンナビノイド受容体結合リガンドを含む組成物

Country Status (10)

Country Link
US (1) US20190343793A1 (enExample)
EP (2) EP3518921B1 (enExample)
JP (1) JP2019534867A (enExample)
KR (1) KR20190060787A (enExample)
CN (1) CN109803650A (enExample)
AU (1) AU2017333420A1 (enExample)
BR (1) BR112019006194A2 (enExample)
CA (1) CA3036313A1 (enExample)
MX (1) MX2019003544A (enExample)
WO (1) WO2018060282A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
KR102295739B1 (ko) 2016-05-03 2021-08-30 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
AU2020216470B2 (en) * 2019-02-01 2023-05-04 Alcon Inc. Compounds, compositions and methods for treatment of myopia
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
JP7883957B2 (ja) 2020-05-18 2026-07-02 マックス バイオロジー カンパニー リミテッド 脂質ポリマー組成物及び使用方法
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
EP4288151A4 (en) 2021-02-03 2025-01-01 ADS Therapeutics LLC Topical ophthalmological compositions
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
CA3234880A1 (en) * 2021-10-13 2023-04-20 Pneuma Respiratory, Inc. Compositions for delivery of cannabinoids
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法
WO2026037894A1 (en) * 2024-08-15 2026-02-19 Dermaliq Therapeutics, Inc. Semifluorinated alkane compositions for cleaning the skin
WO2026047389A1 (en) * 2024-08-30 2026-03-05 Vicadia Lda Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US8809261B2 (en) 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2895144B1 (en) * 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
AU2014332488B2 (en) 2013-10-09 2017-03-09 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511157A (ja) * 1995-09-29 2000-08-29 マイネルト，ハッソ セミフルオロアルカン及びその使用
JP2013513586A (ja) * 2009-12-14 2013-04-22 ノバリック ゲーエムベーハー ドライアイ症候群の治療のための医薬組成物
JP2013540140A (ja) * 2010-10-20 2013-10-31 ノバリック ゲーエムベーハー 有効成分の送達のための液体医薬組成物
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2016109531A1 (en) * 2014-12-30 2016-07-07 Axim Biotechnologies, Inc. Ophthalmic solutions for glaucoma and conjunctivitis treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J DRUG DELIV, vol. 2, no. 4, JPN6021023811, 2004, pages 229 - 240, ISSN: 0004827481 *
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 88, JPN6021023813, 2014, pages 123 - 128, ISSN: 0004827482 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 57, JPN6021023814, 2016, pages 417, ISSN: 0004827483 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073541A (ja) * 2016-12-27 2021-05-13 フェイスブック・テクノロジーズ・リミテッド・ライアビリティ・カンパニーＦａｃｅｂｏｏｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｌｌｃ 触覚デバイスの大規模集積化
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2023543925A (ja) * 2020-10-05 2023-10-18 マックス バイオロジー カンパニー リミテッド カンナビノイド含有組成物及び疾患の処置及び予防のための使用

Also Published As

Publication number Publication date
EP3518921A1 (en) 2019-08-07
MX2019003544A (es) 2019-09-19
CN109803650A (zh) 2019-05-24
BR112019006194A2 (pt) 2019-06-18
EP3698785A1 (en) 2020-08-26
AU2017333420A1 (en) 2019-04-04
US20190343793A1 (en) 2019-11-14
CA3036313A1 (en) 2018-04-05
WO2018060282A1 (en) 2018-04-05
KR20190060787A (ko) 2019-06-03
EP3518921B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
EP3518921B1 (en) Compositions comprising a cannabinoid receptor binding ligand
JP6397472B2 (ja) ドライアイ症候群の治療のための医薬組成物
US9937225B2 (en) Topical formulations and uses thereof
US20200009137A1 (en) Topical formulations and uses thereof
WO2017152129A2 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
HK40036791A (en) Compositions comprising a cannabinoid receptor binding ligand
HK40008248A (en) Compositions comprising a cannabinoid receptor binding ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719